SPAC

Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal
Regenerative medicine biotech Surrozen aims for the Nasdaq in $212M SPAC deal
Fierce Biotech
Surrozen
regenerative medicine
SPAC
Flag link:
It takes two to Tango: The biotech using CRISPR to discover new cancer gene targets rides a $353M SPAC deal to Nasdaq
It takes two to Tango: The biotech using CRISPR to discover new cancer gene targets rides a $353M SPAC deal to Nasdaq
Endpoints
Tango Therapeutics
SPAC
NASDAQ
Flag link:
Immatics takes up the SPAC baton
Immatics takes up the SPAC baton
EP Vantage
SPAC
Immunovant
Immatics
Flag link:
Are SPACs Better Than Traditional IPOs?
Are SPACs Better Than Traditional IPOs?
BioSpace
IPOs
SPAC
Flag link:
The SPAC story departs from the script
The SPAC story departs from the script
EP Vantage
Immunovant
Roivant
SPAC
Flag link:
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Four IPOs and a SPAC pitch a new slate of microbiome, cancer and inflammatory drugs to Wall Street
Endpoints
IPOs
SPAC
Finch Therapeutics
microbiome
Connect Biopharma
Insil Bio
Transcode Therapeutics
Flag link:
The reckoning begins for biotech-focused SPACs
The reckoning begins for biotech-focused SPACs
EP Vantage
SPAC
biotech
funding
Flag link:
Humacyte sets out to bring regenerative medicine to Wall Street, then the world
Humacyte sets out to bring regenerative medicine to Wall Street, then the world
MedCity News
Humacyte
SPAC
M&A
regenerative medicine
Flag link:
Nautilus set to go public in reverse merger with Perceptive SPAC, aims to test proteomics platform with big-name backers
Nautilus set to go public in reverse merger with Perceptive SPAC, aims to test proteomics platform with big-name backers
Endpoints
Nautilus Biotechnology
NASDAQ
SPAC
IPOs
reverse merger
M&A
Arya Sciences
Flag link:
4 takeaways from 23&Me’s planned SPAC deal
4 takeaways from 23&Me’s planned SPAC deal
MedCity News
diagnostics
23andMe
SPAC
Flag link:
23andMe to go public via Richard Branson’s SPAC
23andMe to go public via Richard Branson’s SPAC
Stat
23andMe
Richard Branson
SPAC
genetic testing
Flag link:
5 trends in biotech dealmaking to watch in 2021
5 trends in biotech dealmaking to watch in 2021
BioPharma Dive
biotech
Neuroscience
SPAC
Big Pharma
private equity
Flag link:
Biotech Investors Rolling the Dice with 250% SPAC Surge
Biotech Investors Rolling the Dice with 250% SPAC Surge
BioSpace
biotech
SPAC
Flag link:
Pfizer Spinoff Cerevel Therapeutics Begins Trading on the Nasdaq
Pfizer Spinoff Cerevel Therapeutics Begins Trading on the Nasdaq
BioSpace
Pfizer
Cerevel Therapeutics
SPAC
Arya Sciences
NASDAQ
Flag link:
David Hung’s Nuvation Bio seals merger with blank check firm Panacea
David Hung’s Nuvation Bio seals merger with blank check firm Panacea
Pharmaforum
Nuvation Bio
David Hung
cancer
Panacea
SPAC
Flag link:
Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Endpoints
IPOs
biotech
SPAC
Matthew Roden
Praxis Precision Medicines
Tarsus Pharmaceuticals
Aligos Therapeutics
Kiromic Biopharma
Tumeric Acquisition
Flag link:
It’s Raining Biotech SPACs!
It’s Raining Biotech SPACs!
Forbes
biotech
SPAC
IPOs
Flag link:
A second Carl Icahn protégé jumps in on SPAC spree, as Alex Denner guns for $175M
A second Carl Icahn protégé jumps in on SPAC spree, as Alex Denner guns for $175M
Endpoints
SPAC
Sarissa Capital
Flag link:
More biotechs test the third way to market
More biotechs test the third way to market
EP Vantage
biotech
SPAC
IPOs
Flag link:
Blank check company merger creates cancer specialist Vincera
Blank check company merger creates cancer specialist Vincera
Pharmaforum
SPAC
Vincera
LifeSci Acquisition
oncology
cancer
Bayer
Flag link:

Pages